Michael MBA - Effector Therapeutics Chief Officer
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
Insider
Michael MBA is Chief Officer of Effector Therapeutics
| Age | 47 |
| Phone | 858 925 8215 |
| Web | https://effector.com |
Effector Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.8333) % which means that it has lost $0.8333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.4656) %, meaning that it created substantial loss on money invested by shareholders. Effector Therapeutics' management efficiency ratios could be used to measure how well Effector Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Effector Therapeutics currently holds 19.45 M in liabilities with Debt to Equity (D/E) ratio of 1.03, which is about average as compared to similar companies. Effector Therapeutics has a current ratio of 1.75, which is within standard range for the sector. Note, when we think about Effector Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ronald CPA | RenovoRx | N/A | |
| Carol Zoltowski | Jasper Therapeutics | 74 | |
| Geoffrey Birkett | Ensysce Biosciences | 61 | |
| Susan Prohaska | Jasper Therapeutics | N/A | |
| Ramtin MD | RenovoRx | 58 | |
| Angela Nelms | RenovoRx | 47 | |
| Jeffrey MD | Virpax Pharmaceuticals | 58 | |
| MSE MBA | Ensysce Biosciences | 52 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Jeffrey Meckler | Indaptus Therapeutics | 57 | |
| Anthony MBA | Virpax Pharmaceuticals | 62 | |
| Shana Panzarella | Virpax Pharmaceuticals | N/A | |
| James Ahlers | RenovoRx | 60 | |
| CPA CPA | Virpax Pharmaceuticals | 52 | |
| JD MBA | Virpax Pharmaceuticals | N/A | |
| Jeffrey Millard | Ensysce Biosciences | 48 | |
| Kevin MD | Jasper Therapeutics | 53 | |
| Boyan MD | Indaptus Therapeutics | 57 | |
| Linda Pestano | Ensysce Biosciences | 55 | |
| Walt Esq | Indaptus Therapeutics | 63 | |
Management Performance
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 |
Effector Therapeutics Leadership Team
Elected by the shareholders, the Effector Therapeutics' board of directors comprises two types of representatives: Effector Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Effector. The board's role is to monitor Effector Therapeutics' management team and ensure that shareholders' interests are well served. Effector Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Effector Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Siegfried Reich, CoFounder Board | ||
| Mayank MD, Chief Officer | ||
| Michael MBA, Chief Officer | ||
| Davide Ruggero, CoFounder Board | ||
| Douglas MD, Chief Officer | ||
| Stephen Worland, President CEO | ||
| Kevan Shokat, CoFounder Board |
Effector Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Effector Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | (4.52 M) | ||||
| Shares Outstanding | 4.7 M | ||||
| Shares Owned By Insiders | 2.90 % | ||||
| Shares Owned By Institutions | 23.71 % | ||||
| Number Of Shares Shorted | 91.62 K | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 13.38 X | ||||
| Price To Sales | 69.65 X |
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Effector Stock
| 0.44 | VERA | Vera Therapeutics | PairCorr |
| 0.39 | DSGN | Design Therapeutics | PairCorr |
| 0.37 | VCYT | Veracyte | PairCorr |
| 0.35 | DMAC | DiaMedica Therapeutics Trending | PairCorr |
| 0.33 | DRUG | Bright Minds Biosciences Trending | PairCorr |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |